AU2003279795A1
(en)
*
|
2002-10-04 |
2004-05-04 |
Caritas St.Elisabeth's Medical Center Of Boston, Inc. |
Inhibition of src for treatment of reperfusion injury related to revascularization
|
TW200423938A
(en)
*
|
2003-02-21 |
2004-11-16 |
Wyeth Corp |
4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
|
WO2005046693A1
(en)
*
|
2003-11-06 |
2005-05-26 |
Wyeth |
4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
|
FR2862301B1
(fr)
*
|
2003-11-17 |
2007-12-21 |
Aventis Pharma Sa |
Nouveau procede de preparation de quinoleines 3-fluorees
|
TW200529846A
(en)
*
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
BRPI0516995A
(pt)
*
|
2004-10-22 |
2008-09-30 |
Wyeth Corp |
composto que tem a estrutura
|
CN108421044A
(zh)
|
2005-02-03 |
2018-08-21 |
综合医院公司 |
治疗吉非替尼耐药性癌症的方法
|
CA2608540A1
(en)
*
|
2005-05-18 |
2006-11-23 |
Wyeth |
3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
|
EP1896020B1
(en)
|
2005-06-17 |
2014-08-20 |
The Board of Regents of The University of Texas System |
SKI 606 as src kinase inhibitor for treating osteolytic lesions
|
DK1902029T4
(da)
|
2005-07-01 |
2022-02-28 |
Wyeth Llc |
Krystallinske former af 4-[(2,4-dichlor-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolincarbonitril og fremgangsmåder til fremstilling deraf
|
WO2007056118A1
(en)
|
2005-11-04 |
2007-05-18 |
Wyeth |
Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
|
TW200808728A
(en)
*
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
WO2008060283A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Wyeth |
4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
|
US20080119463A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Wyeth |
4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
|
SI3002009T1
(sl)
|
2007-06-01 |
2021-09-30 |
Wyeth Llc |
Zdravljenje kronične mieloične levkemije, ki je odporna na imatinib, ki ima mutacijo 1457t>c na genu bcrabl, s pomočjo sestavine bosutinib
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
CN101602687A
(zh)
*
|
2008-06-13 |
2009-12-16 |
上海特化医药科技有限公司 |
6-硝基苯乙酮类化合物、其制备方法及用途
|
EP2310011B1
(en)
|
2008-06-17 |
2013-07-24 |
Wyeth LLC |
Antineoplastic combinations containing hki-272 and vinorelbine
|
AU2009279771B2
(en)
|
2008-08-04 |
2015-05-14 |
Wyeth Llc |
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
|
WO2010030835A2
(en)
*
|
2008-09-11 |
2010-03-18 |
Wyeth Llc |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
CN101723854A
(zh)
|
2008-10-24 |
2010-06-09 |
上海特化医药科技有限公司 |
6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
|
KR20220143154A
(ko)
|
2009-04-06 |
2022-10-24 |
와이어쓰 엘엘씨 |
네라티닙을 이용한 유방암의 치료법
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
JP5730389B2
(ja)
|
2010-06-09 |
2015-06-10 |
天津和美生物技術有限公司 |
シアノキノリン誘導体
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
JP2014501235A
(ja)
|
2010-12-13 |
2014-01-20 |
ノバルティス アーゲー |
二量体iap阻害剤
|
EP2680844B1
(en)
|
2011-03-04 |
2016-10-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Amino-quinolines as kinase inhibitors
|
USRE46942E1
(en)
|
2011-07-13 |
2018-07-10 |
Novartis Ag |
4-piperidinyl compounds for use as tankyrase inhibitors
|
CN103781776A
(zh)
|
2011-07-13 |
2014-05-07 |
诺华股份有限公司 |
用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物
|
EP2731951B1
(en)
|
2011-07-13 |
2015-08-19 |
Novartis AG |
4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
WO2013105022A2
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
AR092530A1
(es)
*
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
CN103804353A
(zh)
*
|
2012-11-01 |
2014-05-21 |
常辉 |
一类治疗精神分裂症的化合物及其用途
|
EP2956138B1
(en)
|
2013-02-15 |
2022-06-22 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
ME03061B
(me)
|
2013-02-19 |
2019-01-20 |
Novartis Ag |
Derivati benzotiofena i njihove kompozicije kao selektivni degraderi estrogenskog receptora
|
AU2014219024B2
(en)
|
2013-02-20 |
2018-04-05 |
KALA BIO, Inc. |
Therapeutic compounds and uses thereof
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
AR094707A1
(es)
|
2013-02-21 |
2015-08-19 |
Glaxosmithkline Ip Dev Ltd |
Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
US9789203B2
(en)
|
2013-03-15 |
2017-10-17 |
Novartis Ag |
cKIT antibody drug conjugates
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
CN108530458A
(zh)
|
2013-11-01 |
2018-09-14 |
卡拉制药公司 |
治疗化合物的结晶形式及其用途
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
WO2015107493A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
US9815813B2
(en)
|
2014-01-17 |
2017-11-14 |
Novartis Ag |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
EP2980088A1
(en)
|
2014-07-28 |
2016-02-03 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted isothiazoles
|
US9776970B2
(en)
|
2014-02-20 |
2017-10-03 |
Apotex Inc. |
Bosutinib forms and preparation methods thereof
|
WO2015149727A1
(en)
|
2014-04-02 |
2015-10-08 |
Zentiva, K.S. |
Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
US10238748B2
(en)
|
2014-08-12 |
2019-03-26 |
Novartis Ag |
Anti-CDH6 antibody drug conjugates
|
RU2718914C2
(ru)
|
2014-09-13 |
2020-04-15 |
Новартис Аг |
Сочетанные способы лечения с использованием ингибиторов alk
|
MX2017004360A
(es)
|
2014-10-03 |
2017-06-26 |
Novartis Ag |
Terapias de combinacion.
|
US10774388B2
(en)
|
2014-10-08 |
2020-09-15 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
CN104311485B
(zh)
*
|
2014-10-13 |
2016-08-24 |
烟台市华文欣欣医药科技有限公司 |
一种治疗白血病的药物博舒替尼的制备方法
|
US10005836B2
(en)
|
2014-11-14 |
2018-06-26 |
Novartis Ag |
Antibody drug conjugates
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
EP3789027A1
(en)
|
2015-01-13 |
2021-03-10 |
Kyoto University |
Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
|
AU2016238436A1
(en)
|
2015-03-25 |
2017-08-17 |
Novartis Ag |
Formylated N-heterocyclic derivatives as FGFR4 inhibitors
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
JP6878316B2
(ja)
|
2015-06-19 |
2021-05-26 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物および組成物
|
US10287266B2
(en)
|
2015-06-19 |
2019-05-14 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
US10975080B2
(en)
|
2015-06-19 |
2021-04-13 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
CN105085398A
(zh)
*
|
2015-09-06 |
2015-11-25 |
合肥华方医药科技有限公司 |
一种博舒替尼异构体杂质的制备方法
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
CA3023032A1
(en)
|
2016-05-04 |
2017-11-09 |
Genoscience Pharma |
Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
|
MX2018015625A
(es)
|
2016-06-14 |
2019-03-06 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de shp2.
|
US10336767B2
(en)
|
2016-09-08 |
2019-07-02 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
CA3036340A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
WO2018048747A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
RU2019113504A
(ru)
|
2016-10-07 |
2020-11-09 |
Новартис Аг |
Химерные антигенные рецепторы для лечения рака
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
CA3063983A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
CA3074304A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
CA3153630A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications Sa |
Stable, concentrated radionuclide complex solutions
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
EP3853234A1
(en)
|
2018-09-18 |
2021-07-28 |
Nikang Therapeutics, Inc. |
Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
|
BR112021005513A2
(pt)
|
2018-09-25 |
2021-06-22 |
Black Diamond Therapeutics, Inc. |
derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos
|
WO2020064693A1
(en)
|
2018-09-25 |
2020-04-02 |
Advanced Accelerator Applications (Italy) Srl |
Combination therapy
|
JP2022502496A
(ja)
|
2018-09-25 |
2022-01-11 |
ブラック ダイアモンド セラピューティクス,インコーポレイティド |
チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
|
CN112839715A
(zh)
|
2018-09-29 |
2021-05-25 |
诺华股份有限公司 |
抑制shp2活性化合物的制造方法
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
EP3874030A4
(en)
|
2018-11-01 |
2022-03-09 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
COMPOSITIONS AND METHODS FOR T-CELL ENGINEERING
|
US20240245670A1
(en)
|
2018-12-20 |
2024-07-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
KR20240052881A
(ko)
|
2018-12-21 |
2024-04-23 |
노파르티스 아게 |
Pmel17에 대한 항체 및 이의 접합체
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CA3124935A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
EP4007592A1
(en)
|
2019-08-02 |
2022-06-08 |
LanthioPep B.V. |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
EP4013749A1
(en)
|
2019-08-15 |
2022-06-22 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
BR112022008131A2
(pt)
|
2019-11-01 |
2022-07-19 |
Syngenta Crop Protection Ag |
Compostos heteroaromáticos bicíclicos fundidos pesticidamente ativos
|
AR120563A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quimérico cd19 y cd22 y sus usos
|
AU2020410266A1
(en)
|
2019-12-20 |
2022-06-30 |
Novartis Ag |
Combination of anti TIM-3 antibody MBG453 and anti TGF-beta antibody NIS793, with or without decitabine or the anti PD-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
IL298262A
(en)
|
2020-06-23 |
2023-01-01 |
Novartis Ag |
A dosage regimen that includes derivatives of 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
IL303661A
(en)
|
2020-12-22 |
2023-08-01 |
Nikang Therapeutics Inc |
COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY
|
WO2022152821A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
EP4323349A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
EP4323350A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
KR20240024926A
(ko)
|
2021-06-24 |
2024-02-26 |
신젠타 크롭 프로텍션 아게 |
살충제로서의 2-[3-[1[(퀴나졸린-4-일)아미노]에틸]피라진-2-일]티아졸-5-카르보니트릴 유도체 및 유사한 화합물
|
EP4370522A1
(en)
|
2021-07-14 |
2024-05-22 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
WO2023192801A1
(en)
|
2022-03-28 |
2023-10-05 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023247360A1
(en)
|
2022-06-21 |
2023-12-28 |
Syngenta Crop Protection Ag |
Pesticidally active fused bicyclic heteroaromatic compounds
|
WO2024023666A1
(en)
|
2022-07-26 |
2024-02-01 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|
CN115286573A
(zh)
*
|
2022-08-04 |
2022-11-04 |
常州工程职业技术学院 |
一种1-烷氧基异喹啉化合物的绿色合成方法
|
WO2024102849A1
(en)
|
2022-11-11 |
2024-05-16 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|